mi-IMAGING PIPELINE
multimmune's mi-IMAGING (im) platform is based on mi-TPPim - a 14mer peptide which recognizes membrane Hsp70 which is selectively expressed on tumor cells (EPO patent granted) and mi-TUMEXim - a membrane Hsp70-specific monoclonal antibody.
mi-TPPim: Imaging peptide
- Improved ex vivo fluorescence imaging of human head and neck cancer using the peptide tracer TPP-IRDye800 targeting membrane-bound Hsp70 on tumor cells
- Functionalized hybrid iron oxide-gold nanoparticles targeting membrane Hsp70 radiosensitize triple-negative breast cancer cells by ROS-mediated apoptosis
- Targeted Hsp70 fluorescence molecular endoscopy detects dysplasia in Barrett's esophagus
- Preclinical evaluation of the Hsp70 peptide tracer TPP-PEG24-DFO[89Zr] for tumor-specific PET/CT imaging
- Selective in vivo imaging of syngeneic, spontaneous, and xenograft tumors using a novel tumor cell-specific hsp70 peptide-based probe
mi-TUMEXim: Imaging monoclonal antibody
mi-TUMEXim provides a valuable platform for multimodal imaging of tumors and metastases that will improve our understanding of tumorigenesis and allow the establishment of improved diagnostic procedures and more accurate therapeutic monitoring. mi-TUMEXim also provides a promising platform for tumor-specific drug delivery and other membrane Hsp70-based targeted therapies.
Intraoperative detection of CT26 colon carcinoma cell-derived tumors using the mi-TUMEXim-Cy5.5 monoclonal antibody